Zentrum fuer klinische Studien Suedbrandenburg GmbH

Elsterwerda 04910

2 studies enrolling now · 11 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, Cardiovascular Risk, Chronic Kidney Disease, Diabetes Mellitus, Type 2, Heart Failure, Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2, Obesity, Overweight, Type 2 Diabetes (T2D), Type 2 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

Studies at this site

• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
• A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) — Completed
• AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight — Starting soon
• A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight — Completed
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight — Running, not enrolling
• A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes — Completed
• Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity — Completed
• Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes — Completed
• Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight — Running, not enrolling
• Levels of Inflammation in People With Cardiovascular Disease (POSEIDON) — Completed
• Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity — Completed